Skip to content

Chinese medicine Chaihu-jia-Longgu-Muli-tang in the treatment of depression: a multi-center, randomized, open lable, controlled trial

Chinese medicine Chaihu-jia-Longgu-Muli-tang in the treatment of depression: a multi-center, randomized, open lable, controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17013173
Enrollment
Unknown
Registered
2017-10-30
Start date
2017-10-31
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Test group A1:Chaihu-jia-Longgu-Muli-tang
Test group A2:Chai Mu jiaqiang Decoction
Control group A0:Escitalopram
Test group B1:Chaihu-jia-Longgu-Muli-tang+Escitalopram
Control group B0:Lorazepam+Escitalopram

Sponsors

Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged ? 18 years; 2. The patients met the criteria for the diagnosis of ICD-10 depression episode (F32) or recurrent depression (F33); 3. According to the doctor's judgment, the patient's educational level can complete the task of reading and completing the questionnaire; 4. According to the doctor's judgment, the patient can complete the follow-up task; 5. Patients can receive standardized drug treatment; 6. The standard for depression episodes: HAMD-17 >7 scores; 7. Standard: PSQI ?6 insomnia.;Inclusion criteria: 1. Patients aged ? 18 years; 2. The patients met the criteria for the diagnosis of ICD-10 depression episode (F32) or recurrent depression (F33); 3. According to the doctor's judgment, the patient's educational level can complete the task of reading and completing the questionnaire; 4. According to the doctor's judgment, the patient can complete the follow-up task; 5. Patients can receive standardized drug treatment; 6. The standard for depression episodes: HAMD-17 >7 scores; 7. Standard: PSQI ?6 insomnia.;Inclusion criteria: 1. Patients aged ? 18 years; 2. The patients met the criteria for the diagnosis of ICD-10 depression episode (F32) or recurrent depression (F33); 3. According to the doctor's judgment, the patient's educational level can complete the task of reading and completing the questionnaire; 4. According to the doctor's judgment, the patient can complete the follow-up task; 5. Patients can receive standardized drug treatment; 6. The standard for depression episodes: HAMD-17 >7 scores; 7. Standard: PSQI ?6 insomnia.;Inclusion criteria: 1. Patients aged ? 18 years; 2. The patients met the criteria for the diagnosis of ICD-10 depression episode (F32) or recurrent depression (F33); 3. According to the doctor's judgment, the patient's educational level can complete the task of reading and completing the questionnaire; 4. According to the doctor's judgment, the patient can complete the follow-up task; 5. Patients can receive standardized drug treatment; 6. The standard for depression episodes: HAMD-17 >7 scores; 7. Standard: PSQI ?6 insomnia.;Inclusion criteria: 1. Patients aged ? 18 years; 2. The patients met the criteria for the diagnosis of ICD-10 depression episode (F32) or recurrent depression (F33); 3. According to the doctor's judgment, the patient's educational level can complete the task of reading and completing the questionnaire; 4. According to the doctor's judgment, the patient can complete the follow-up task; 5. Patients can receive standardized drug treatment; 6. The standard for depression episodes: HAMD-17 >7 scores; 7. Standard: PSQI ?6 insomnia.

Exclusion criteria

Exclusion criteria: Bipolar disorders, schizophrenia, suicidal tendencies, emotional disorders, severe organic diseases or physical illness that significantly affect social function of patients.According to the doctor's judgment, patients can not comply with this research program.;Exclusion criteria: Bipolar disorders, schizophrenia, suicidal tendencies, emotional disorders, severe organic diseases or physical illness that significantly affect social function of patients.According to the doctor's judgment, patients can not comply with this research program.;Exclusion criteria: Bipolar disorders, schizophrenia, suicidal tendencies, emotional disorders, severe organic diseases or physical illness that significantly affect social function of patients.According to the doctor's judgment, patients can not comply with this research program.;Exclusion criteria: Bipolar disorders, schizophrenia, suicidal tendencies, emotional disorders, severe organic diseases or physical illness that significantly affect social function of patients.According to the doctor's judgment, patients can not comply with this research program.;Exclusion criteria: Bipolar disorders, schizophrenia, suicidal tendencies, emotional disorders, severe organic diseases or physical illness that significantly affect social function of patients.According to the doctor's judgment, patients can not comply with this research program.

Design outcomes

Primary

MeasureTime frame
improvement rate of Depression;Onset time of antidepressant;improvement rate of insomnia;

Secondary

MeasureTime frame
Somatization symptoms;side effect;

Countries

China

Contacts

Public ContactGang Chen;Gang Chen;Gang Chen;Gang Chen;Gang Chen ;;;;

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine;Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine;Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine;Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine;Affiliated Hospital of Integrated Tradit

chengang@njucm.edu.cn;chengang@njucm.edu.cn;chengang@njucm.edu.cn;chengang@njucm.edu.cn;chengang@njucm.edu.cn+86 17396809245;+86 17396809245;+86 17396809245;+86 17396809245;+86 17396809245

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026